BARI, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.985
EU - Europa 4.653
AS - Asia 4.506
SA - Sud America 692
AF - Africa 167
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 8
Totale 21.046
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.779
GB - Regno Unito 1.797
SG - Singapore 1.324
CN - Cina 1.156
IT - Italia 840
HK - Hong Kong 538
BR - Brasile 511
VN - Vietnam 489
DE - Germania 427
SE - Svezia 357
FR - Francia 283
BD - Bangladesh 249
FI - Finlandia 204
RU - Federazione Russa 190
UA - Ucraina 184
TR - Turchia 165
CA - Canada 103
IN - India 103
KR - Corea 102
ID - Indonesia 75
BG - Bulgaria 72
AR - Argentina 61
MA - Marocco 56
MX - Messico 50
IQ - Iraq 43
ZA - Sudafrica 43
JP - Giappone 37
BE - Belgio 33
ES - Italia 33
PK - Pakistan 32
PL - Polonia 32
AU - Australia 31
LT - Lituania 30
EC - Ecuador 29
IE - Irlanda 29
NL - Olanda 28
AT - Austria 26
PH - Filippine 25
SA - Arabia Saudita 25
CO - Colombia 24
AE - Emirati Arabi Uniti 21
CL - Cile 20
CZ - Repubblica Ceca 20
UZ - Uzbekistan 17
IR - Iran 13
JO - Giordania 13
MY - Malesia 13
KE - Kenya 12
CH - Svizzera 11
PY - Paraguay 11
VE - Venezuela 11
EG - Egitto 10
AZ - Azerbaigian 9
BO - Bolivia 9
CR - Costa Rica 9
PT - Portogallo 9
JM - Giamaica 8
DZ - Algeria 7
GR - Grecia 7
KG - Kirghizistan 7
NO - Norvegia 7
PE - Perù 7
UY - Uruguay 7
BH - Bahrain 6
DO - Repubblica Dominicana 6
EU - Europa 6
KZ - Kazakistan 6
NP - Nepal 6
RO - Romania 6
ET - Etiopia 5
HU - Ungheria 5
IL - Israele 5
LB - Libano 5
RS - Serbia 5
SV - El Salvador 5
TZ - Tanzania 5
AL - Albania 4
BZ - Belize 4
GH - Ghana 4
NG - Nigeria 4
NI - Nicaragua 4
NZ - Nuova Zelanda 4
PA - Panama 4
PS - Palestinian Territory 4
TH - Thailandia 4
TN - Tunisia 4
CI - Costa d'Avorio 3
GP - Guadalupe 3
OM - Oman 3
SN - Senegal 3
CY - Cipro 2
DM - Dominica 2
HN - Honduras 2
HR - Croazia 2
MT - Malta 2
PR - Porto Rico 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
UG - Uganda 2
Totale 21.016
Salva come PNG Salva come JPEG
Città #
Southend 1.448
Ashburn 1.095
Fairfield 1.059
Santa Clara 939
Singapore 838
Woodbridge 702
Hong Kong 528
Houston 509
Chandler 497
Seattle 445
San Jose 426
Wilmington 401
Cambridge 380
Ann Arbor 327
Jacksonville 315
Beijing 273
Dearborn 261
Hefei 252
Nyköping 246
Los Angeles 206
Chicago 203
Council Bluffs 199
London 192
Modena 183
New York 158
Ho Chi Minh City 154
Helsinki 132
Hanoi 111
San Diego 106
Seoul 97
Shanghai 97
The Dalles 97
Frankfurt am Main 95
Milan 92
Salt Lake City 82
Princeton 76
Moscow 70
Sofia 70
Izmir 64
Buffalo 63
São Paulo 63
Eugene 61
Munich 60
Jakarta 55
Lauterbourg 52
Dallas 50
Casablanca 42
Columbus 39
Bologna 37
Rome 37
Bremen 35
Elk Grove Village 34
Redwood City 33
Fremont 31
Phoenix 31
Montreal 30
Boardman 28
Brussels 28
Da Nang 28
Toronto 28
Warsaw 28
Falls Church 27
Dublin 26
Tampa 26
Miami 24
Orem 23
Tokyo 23
Johannesburg 22
Dong Ket 20
Sterling 19
Turku 19
Denver 17
Dhaka 17
Nanjing 17
Norwalk 17
Rio de Janeiro 17
Brooklyn 16
Chengdu 16
Des Moines 16
Lancaster 16
Baghdad 15
Guangzhou 15
Poplar 15
Atlanta 14
Nuremberg 14
Guayaquil 13
Paris 13
San Giuliano Milanese 13
Stockholm 13
Tashkent 13
Amsterdam 12
Buenos Aires 12
Detroit 12
Mumbai 12
Newark 12
Amman 11
Boston 11
Chennai 11
Florence 11
Haiphong 11
Totale 14.949
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 623
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 529
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 492
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 469
The undergraduate nursing student evaluation of clinical learning environment: an Italian survey [La valutazione dell'ambiente di apprendimento clinico da parte degli studenti del Corso di Laurea in Infermieristica: una indagine italiana] 465
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 457
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 443
Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit 440
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 417
Empathic attitudes among nursing students: a preliminary study 414
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 411
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 392
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 386
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) 385
Activity of BKM120 and BEZ235 against lymphoma cells 373
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 367
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 364
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 363
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 349
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 346
A concise review of lenalidomide therapy for follicular lymphoma 341
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 337
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 334
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 327
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 321
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 316
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 314
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 312
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 311
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 311
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: A phase III randomized study by the fondazione Italiana linfomi 311
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 309
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 306
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 305
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma 292
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 288
Genomic profiling of enzastaurin-treated B cell lymphoma RL cells 288
Rapid loss of response after withdrawal of treatment with azacitidine: A case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 287
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 284
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 283
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 280
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 278
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 269
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 269
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 264
Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL) 260
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial 256
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 252
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 251
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 245
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 244
Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? 241
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 237
Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: Results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL) 231
NATURAL HISTORY OF CRYOGLOBULINEMIA FROM 2000 TO 2018 FROM THE LABORATORY POINT OF VIEW: AN ANALYSIS OF CRYOGLOBULIN CHARACTERISTICS IN A SINGLE CENTER. 230
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 227
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 224
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi 190
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi 184
Khorana score and histotype predicts incidence of early venous thromboembolism in Non-Hodgkin lymphomas: A Pooled-Data analysis of 12 clinical trials of fondazione italiana linfomi (FIL) 184
Management of lymphoma survivor patients in Italy: an evaluation by Fondazione Italiana Linfomi 184
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 183
The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis 179
Diagnosi di crioproteinemia: preziosa collaborazione tra laboratorio e clinica per la corretta gestione di una patologia rara 177
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 174
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study 139
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature 139
Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma. A Systematic Review by the Fondazione Italiana Linfomi 121
The impact of healthy lifestyles on late sequelae in classical hodgkin lymphoma and diffuse large b-cell lymphoma survivors. A systematic review by the fondazione italiana linfomi 119
Correction to: The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of pet-guided treatments (Annals of Hematology, (2020), 99, 2, (277-282), 10.1007/s00277-019-03893-7) 117
Management of adverse events and supportive therapy in relapsed/refractory multiple myeloma 115
Management of multiple myeloma|Terapia del mieloma multiplo 94
Totale 21.219
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.442
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.442
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.487 62 110 181 64 28 119 83 112 150 112 266 200
2022/20231.396 152 185 113 141 152 196 25 131 180 13 66 42
2023/20241.099 58 38 75 106 232 72 199 101 33 19 63 103
2024/20253.171 104 40 76 245 645 494 220 181 361 119 255 431
2025/20266.668 406 254 440 794 1.106 417 724 390 648 571 503 415
2026/2027130 130 0 0 0 0 0 0 0 0 0 0 0
Totale 21.219